Rabe-20 Tablet: Each enteric coated tablet contains Rabeprazole Sodium BP 20 mg.
Rabe-20 Capsule: Each vegetable capsule shell contains Rabeprazole Sodium BP 20 mg as enteric coated pellets.
Rabeprazole suppresses gastric acid secretion by inhibiting the gastric H+/K+ ATPase at the secretory surface of the gastric parietal cell. Because this enzyme is regarded as the acid (proton) pump within the parietal cell, Rabeprazole has been characterized as a gastric proton-pump inhibitor.
Swallow whole with or without food.
Rabeprazole like other PPIs is metabolized through Cytochrome P450 drug metabolizing enzyme system. But Rabeprazole does not have clinically significant interaction with other drugs metabolized by CYP P450 system, such as warfarin, theophylline, diazepam and phenytoin. Rabeprazole inhibits gastric acid secretion and may interfere with absorption of drugs where gastric pH is an important determinant of bioavailability e.g. ketoconazole, iron salts and digoxin. In studies no interaction with liquid antacid or foods was observed.
Rabeprazole is contraindicated in patients with known hypersensitivity to Rabeprazole or to any component of the formulation.
Rabeprazole
is generally well tolerated. The observed undesirable effects have been generally mild/moderate and transient in nature. The most common adverse events are headache, diarrhea and nausea. The less common adverse effects are abdominal pain, asthenia, flatulence, rash, dry mouth etc.
Use in pregnancy & lactation: Glucosamine should not be taken by pregnant women and nursing mothers due to lack of scientific data regarding its effect on fetus and infants. Diacerein is contraindicated in pregnant women and lactating mothers.
Pediatric use: No data regarding pediatric dosage is available.
Hepatic Impairment: No sufficient data was found regarding the use of this combination in patient with hepatic insufficiency.
Renal Impairment: In case of patients with Creatinine Clearance (CrCl) <30 ml/min the dose should be reduced.
Administration of Rabeprazole to patients with mild to moderate liver impairment results in increased exposure and decreased elimination. Caution should be exercised in patients with severe hepatic impairment.
Store below 25 C temperature at dry place, protect from light. Keep out of the reach of children.